Anthony Zulli

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Molecular Docking

Respiratory Syndrome Coronavirus

Top Venues

Expert opinion on therapeutic targets

This page only lists publications with an associated author ORCID identifier.

Publications

Harry Ridgway, Graham J Moore, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, Weronika Hoffmann, Katarzyna Węgrzyn, Niki Vassilaki, George Mpekoulis, Marios Zouridakis, Petros Giastas, Veroniki P Vidali, Konstantinos Kelaidonis, Minos-Timotheos Matsoukas, Marios Dimitriou, Thomas Mauromoustakos, Sotirios Tsiodras, Vassilis G Gorgoulis, Ioannis Karakasiliotis, Christos T Chasapis, John M Matsoukas
Novel benzimidazole angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies. Expert opinion on therapeutic targets 28 (5) (2024)
Harry Ridgway, Graham J Moore, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, Weronika Hoffmann, Katarzyna Węgrzyn, Niki Vassilaki, George Mpekoulis, Marios Zouridakis, Petros Giastas, Veroniki P Vidali, Konstantinos Kelaidonis, Minos-Timotheos Matsoukas, Marios Dimitriou, Thomas Mauromoustakos, Sotirios Tsiodras, Vassilis G Gorgoulis, Ioannis Karakasiliotis, Christos T Chasapis, John M Matsoukas
Novel benzimidazole angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies. Expert opinion on therapeutic targets (2024)
Harry Ridgway, Graham J Moore, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, Weronika Hoffmann, Katarzyna Węgrzyn, Niki Vassilaki, George Mpekoulis, Marios Zouridakis, Petros Giastas, Veroniki P Vidali, Konstantinos Kelaidonis, Minos-Timotheos Matsoukas, Marios Dimitriou, Thomas Mauromoustakos, Sotirios Tsiodras, Vassilis G Gorgoulis, Ioannis Karakasiliotis, Christos T Chasapis, John M Matsoukas
Novel benzimidazole angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies. Expert opinion on therapeutic targets 28 (5) (2024)